Triple Hair’s Feature in the NY Post

Media

Triple Hair is pleased to share that its proof-of-concept trial results have been featured in the New York Post. The article, titled “New triple-threat topical treatment fights hair loss better than finasteride and minoxidil,” highlights the promising findings from our TH-07 research- read the full article her

Read the full publication here: https://nypost.com/2026/03/16/health/triple-threat-fights-hair-loss-better-than-finasteride-and-minoxidil/

About Triple Hair

Triple Hair Group Inc. is a Canadian biotechnology company focused on the development of innovative therapies for androgenic alopecia, a condition affecting hundreds of millions of men and women worldwide.

The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options.

Triple Hair’s lead product candidate, TH07, is a patented prescription topical therapy currently in Phase III clinical development.

For more information, visit the Company’s website, at www.triplehair.ca/investors.

Contact:
Triple Hair Group
Jean-Philippe Gravel
President and CEO
investors@triplehair.ca